Actively Recruiting
Application of 68GA-labeled CD73 Targeting Probe PET/CT Imaging in the Diagnosis of Breast Cancer
Led by Peking Union Medical College Hospital · Updated on 2025-06-17
50
Participants Needed
1
Research Sites
81 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The investigators plan to conduct a 68Ga-DOTA-dPNE PET/CT imaging study in breast cancer patients to observe the binding of the tracer to tumor lesions and evaluate CD73 expression. As part of the study design, a subset of patients will initially undergo dynamic PET/CT imaging to evaluate the safety profile and pharmacokinetic distribution of the radiotracer in vivo. Subsequently, static PET/CT imaging will be performed on additional patients to assess the diagnostic effectiveness of 68Ga-DOTA-dPNE. Imaging results will be correlated with relevant clinical indicators to evaluate the potential of this tracer in diagnosing breast cancer, guiding therapeutic decisions, and predicting responses to targeted therapies.
CONDITIONS
Official Title
Application of 68GA-labeled CD73 Targeting Probe PET/CT Imaging in the Diagnosis of Breast Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female patients aged 18 years or older
- Expected survival of at least 12 weeks
- No prior radiotherapy or chemotherapy
- Surgery or biopsy feasible for pathological diagnosis
- At least one measurable target lesion as defined by RECIST v1.1
- Able to provide written informed consent and comply with follow-up requirements
You will not qualify if you...
- Severe liver or kidney dysfunction
- Pregnant, breastfeeding, planning to become pregnant, or planning to have children during the study period
- Women of childbearing potential must use effective contraception during the study
- Unable to lie flat for 30 minutes
- History of claustrophobia or other psychiatric disorders
- Any other condition deemed unsuitable for participation by the investigator
- Refusal to participate in the clinical study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
PUMCH
Dongcheng, Beijing Municipality, China, 100730
Actively Recruiting
Research Team
C
Chenhao JIA
CONTACT
X
Xianzhong ZHANG
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here